Lilly Company Profile

✉ Email this page to a colleague

LILLY has one hundred and five approved drugs.

There is one US patent protecting LILLY drugs.

There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-six supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	SECONAL SODIUM	secobarbital sodium	SUPPOSITORY;RECTAL	086530-004	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Lilly	ISONIAZID	isoniazid	TABLET;ORAL	008499-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Lilly	TAZIDIME IN PLASTIC CONTAINER	ceftazidime	INJECTABLE;INJECTION	062739-001	Jul 10, 1986		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	5,641,790	⤷ Try a Trial
Lilly	DECABID	indecainide hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019693-001	Dec 29, 1989	4,389,393	⤷ Try a Trial
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-002	Sep 7, 2007	5,217,974*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Capsules	40 mg	➤ Subscribe	2012-05-10
➤ Subscribe	Capsules	6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg	➤ Subscribe	2005-01-10
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2005-11-01
➤ Subscribe	For Injection	2 g/vial	➤ Subscribe	2007-08-24
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2008-02-04
➤ Subscribe	For Injection	750 mg/vial	➤ Subscribe	2016-10-06
➤ Subscribe	Tablets	2.5 mg	➤ Subscribe	2008-10-14
➤ Subscribe	Delayed-release Capsules	20 mg, 30 mg and 60 mg	➤ Subscribe	2008-08-04
➤ Subscribe	Capsules	10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg	➤ Subscribe	2007-05-29
➤ Subscribe	Capsules	3 mg/25 mg	➤ Subscribe	2008-05-08
➤ Subscribe	For Injection	1g/vial	➤ Subscribe	2005-11-14
➤ Subscribe	For Injection	100 mg/vial	➤ Subscribe	2008-07-01
➤ Subscribe	For Injection	1000 mg/vial	➤ Subscribe	2012-06-27
➤ Subscribe	Injection	250 mcg/mL, 2.4 mL prefilled Pen	➤ Subscribe	2015-07-27
➤ Subscribe	Tablets	5 mg, 10 mg and 20 mg	➤ Subscribe	2007-11-21

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0273658	C300171	Netherlands	⤷ Try a Trial	PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811
0933372	PA2008006	Lithuania	⤷ Try a Trial	PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
1441735	08C0026	France	⤷ Try a Trial	PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.